Comparing chemo plus stem cell transplant to chemo alone for AL amyloidosis
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of AL amyloidosis (a protein buildup disease).
- You must have measurable signs of the disease, like abnormal proteins in your blood or urine.
- You can start the study if you are 18 or older and your overall health is fairly good (able to care for yourself).
- Your heart must be healthy enough: no severe heart problems, and specific heart tests must be within safe limits.
- You must be willing to possibly receive high-dose chemotherapy and a stem cell transplant if assigned to that group.
- You cannot have certain other conditions like uncontrolled diabetes, active hepatitis, or severe asthma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether giving daratumumab as ongoing maintenance therapy after your initial AL amyloidosis treatment can improve survival. It may help by keeping the disease under control longer after you have responded to induction therapy.
This trial tests whether an autologous stem cell transplant (using your own stem cells) can help people with newly diagnosed AL amyloidosis. It may be offered to help your body reset abnormal disease-producing cells, based on your health and test results.
This trial tests a type of immunotherapy called CAR-T cells for people newly diagnosed with severe AL amyloidosis, a disease where abnormal proteins damage organs, especially the heart. It aims to see if this treatment can help control the disease.
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
This early-stage trial tests a new cell therapy using your own immune cells (genetically modified to target amyloid-producing cells) to treat light chain amyloidosis that hasn't responded to standard treatments. The goal is to help patients whose disease has come back or stopped responding to previous therapies.
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.